B
Bull
Bull · 25%RENB
$0.38
Szenariopreis
$1.420
+0.173 (+12.16%)Zum Schluss
Loading chart…
- High
- 1.430
- Open
- 1.190
- VWAP
- 1.33
- Vol
- 896.30K
- Mkt Cap
- 230.89M
- Low
- 1.130
- Amount
- 1.19M
- EV/EBITDA, TTM
- 0.00
Lunai Bioworks, Inc., formerly Renovaro Inc., is focused on AI-powered biodefense, drug discovery and advanced diagnostics. The Company is engaged in harnessing advanced computational biology and AI/machine learning to accelerate drug discovery, diagnostics and strengthen biosecurity capabilities. From high-resolution phenotyping to predictive disease modeling, the Company is pioneering a new era of precision diagnostics-where early detection, patient stratification, and therapeutic targeting converge into a single, adaptive platform. These are designed to transform clinical decision-making, reduce time-to-treatment, and unlock previously inaccessible insights from biological data. Its proprietary platforms in translational analytics, in vivo modeling, and machine vision-accelerating biomarker discovery and therapeutic development in precision neurology and infectious disease.
Bewertungskennzahlen
The current forward P/E ratio for Lunai Bioworks Inc (RENB) is 0.00, compared to its 5-year average forward P/E of 0.00.
Alphio AI Price Scenarios for RENB
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Event-Zeitleiste
News
2.009-28TipRanksStock Splits Scheduled for This Week (September 29 to October 3) – Keep Your Investments Active
8.509-25BenzingaPepGen Shares Surge 112%; Check Out 20 Stocks Making Moves in Premarket Trading
3.009-09BenzingaThree Health Care Stocks You Won't Want to Overlook in Q3
8.508-19GlobenewswireInvestor Alert from Former Louisiana Attorney General: Kahn Swick & Foti, LLC Examines Price and Process in Predictive Oncology Inc. (POAI) Proposed Sale
8.007-29PRnewswireAI Just Got a Green Light from the White House--Here's What That Means for Healthcare Stocks
RENB FAQ — answered by Alphio AI
Lunai Bioworks, Inc., formerly Renovaro Inc., is focused on AI-powered biodefense, drug discovery and advanced diagnostics. The Company is engaged in harnessing advanced computational biology and AI/machine learning to accelerate drug discovery, diagnostics and strengthen biosecurity capabilities. From high-resolution phenotyping to predictive disease modeling, the Company is pioneering a new era of precision diagnostics-where early detection, patient stratification, and therapeutic targeting converge into a single, adaptive platform. These are designed to transform clinical decision-making, reduce time-to-treatment, and unlock previously inaccessible insights from biological data. Its proprietary platforms in translational analytics, in vivo modeling, and machine vision-accelerating biomarker discovery and therapeutic development in precision neurology and infectious disease. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.